Show simple item record

dc.contributor.authorKopetz, S
dc.contributor.authorGrothey, A
dc.contributor.authorYaeger, R
dc.contributor.authorVan, CE
dc.contributor.authorDesai, J
dc.contributor.authorYoshino, T
dc.contributor.authorWasan, H
dc.contributor.authorCiardiello, F
dc.contributor.authorLoupakis, F
dc.contributor.authorHong, YS
dc.contributor.authorSteeghs, N
dc.contributor.authorGuren, TK
dc.contributor.authorArkenau, HT
dc.contributor.authorGarcia-Alfonso, P
dc.contributor.authorPfeiffer, P
dc.contributor.authorOrlov, S
dc.contributor.authorLonardi, S
dc.contributor.authorElez, E
dc.contributor.authorKim, TW
dc.contributor.authorSchellens, JHM
dc.contributor.authorGuo, C
dc.contributor.authorKrishnan, A
dc.contributor.authorDekervel, J
dc.contributor.authorMorris, V
dc.contributor.authorCalvo, FA
dc.contributor.authorTarpgaard, LS
dc.contributor.authorBraun, Michael S
dc.contributor.authorGollerkeri, A
dc.contributor.authorKeir, C
dc.contributor.authorMaharry, K
dc.contributor.authorPickard, M
dc.contributor.authorChristy-Bittel, J
dc.contributor.authorAnderson, L
dc.contributor.authorSandor, V
dc.contributor.authorTabernero, J
dc.date.accessioned2019-11-19T16:00:59Z
dc.date.available2019-11-19T16:00:59Z
dc.date.issued2019en
dc.identifier.citationKopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-43.en
dc.identifier.pmid31566309en
dc.identifier.doi10.1056/NEJMoa1908075en
dc.identifier.urihttp://hdl.handle.net/10541/622411
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1056/NEJMoa1908075en
dc.titleEncorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal canceren
dc.typeArticleen
dc.contributor.departmentUniversity of Texas M.D. Anderson Cancer Center, Houstonen
dc.identifier.journalNew England Journal of Medicineen


This item appears in the following Collection(s)

Show simple item record